Essex Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Essex Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,284	Closed	-$817K	–	339
2015 Q4	$817K	Hold	4,284	–	–	0.13%	172
2015 Q3	$670K	Hold	4,284	–	–	0.11%	191
2015 Q2	$774K	Sell	4,284 -2,038	-32%	-$352K	0.12%	187
2015 Q1	$1.1M	Buy	6,322 +2,740	+76%	+$496K	0.15%	145
2014 Q4	$663K	Sell	3,582 -6	-0.2%	-$1.11K	0.1%	195
2014 Q3	$595K	Sell	3,588 -15	-0.4%	-$2.46K	0.09%	211
2014 Q2	$563K	Sell	3,603 -523	-13%	-$82.6K	0.08%	237
2014 Q1	$628K	Sell	4,126 -1,511	-27%	-$240K	0.09%	230
2013 Q4	$749K	Buy	5,637 +536	+11%	+$64.3K	0.11%	229
2013 Q3	$593K	Sell	5,101 -2,036	-29%	-$223K	0.09%	231
2013 Q2	$658K	Buy	+7,137	New	+$688K	0.12%	199

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Essex Investment Management's ALXN Position: Q1 2016 in Review

Essex Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 4,284 shares — an estimated $817K sold.

Essex Investment Management first reported a position in ALXN in Q2 2013 and held it in 11 quarters. The position peaked at $1.1M in Q1 2015. 519 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

Essex Investment Management reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Essex Investment Management sold 4,284 Alexion Pharmaceuticals shares in Q1 2016, an estimated $817K.
Essex Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Essex Investment Management's Alexion Pharmaceuticals position peaked at $1.1M in Q1 2015.
519 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Essex Investment Management's 13F filing for Q1 2016, filed 9 May 2016.